Q-Line Biotech IPO
Market Sentiment
IPO Details
Market Lot Size
IPO Reservation
Day-wise Subscription (times subscribed)
Financial Analysis
| Metric | 2023 | 2024 | 2025 | Dec 2025 |
|---|---|---|---|---|
| Revenue | 184.81 | 206.45 | 322.58 | 236.50 |
| Expense | 154.97 | 175.85 | 261.43 | 186.96 |
| Profit (PAT) | 32.10 | 34.44 | 28.13 | 38.69 |
| Total Assets | 251.58 | 339.25 | 455.49 | 561.34 |
| Company | EPS | P/E |
|---|---|---|
| Powerica Limited | 15.26 | 24.45 |
| Cummins India Limited | 72.15 | 64.13 |
| Kirloskar Oil Engines Limited | 33.71 | 43.24 |
| NTPC Green Energy Limited | 0.67 | 129.40 |
| Acme Solar Holdings Limited | 4.55 | 50.74 |
| Adani Green Energy Limited | 8.37 | 101.53 |
Promoters: Saurabh Garg, Amita Garg, Ayush Garg, Ajay Kumar Mahanty and Abhay Agrawal
| Shareholding | No. of Shares | Holding % |
|---|---|---|
| Promoter Holding Pre Issue | 1,70,74,999 | 96.77% |
Strengths & Risks
- Heavily oversubscribed — 102.5x overall (so far).
- Strong institutional (QIB) demand — 123.9x.
- Revenue grew 56% in the latest reported year.
- Solid profit margin — 8.7%.
- Strong return on equity — 18%.
- Lists on the exchange's SME platform, where trading is usually thinner than on the main board — selling at your price can be harder.
Compiled from this issue's live GMP, subscription, valuation and financial data, and updated as those figures change. Informational only — not investment advice. Always read the RHP before applying.
Company Information
Since its incorporation in 2013, Q-Line Biotech has been involved in the healthcare and diagnostic industry. The firm is known for manufacturing and supplying In-Vitro Diagnostic (IVD) products, medical diagnostic equipment, reagents, rapid test kits, and pathology instruments. The firm has been known to offer high-quality products and services at an affordable price range. Q-Line Biotech has over 15 years of experience in the diagnostic industry and has served 150+ national and international clients. Moreover, the company also has 12 years of experience in developing and manufacturing various products. Its product range includes haematology, POC testing, clinical chemistry, molecular diagnostics, rapid tests, ELISA, and special diagnostics.
Q-Line Biotech Ltd., 298-281,, Transport Nagar,, Kanpur Road Adjacent Transport Nagar Metro Station, Lucknow, Uttar Pradesh, 226012
| Purpose | Amount (Cr) |
|---|---|
| To meet Working Capital requirements | 110.00 |
| Repayment of certain borrowing availed by the Company, in part or full | 90.00 |
| General Corporate Purpose | - |
Resources & Documents
Q-Line Biotech has set a price band of Rs 326–Rs 343 per share for an issue size of Rs 214 crore. The stock listed with a 31.78% gain versus its issue price on May 29, 2026.
Since its incorporation in 2013, Q-Line Biotech has been involved in the healthcare and diagnostic industry. The firm is known for manufacturing and supplying In-Vitro Diagnostic (IVD) products, medical diagnostic equipment, reagents, rapid test kits, and pathology instruments.
The issue is promoted by Saurabh Garg, Amita Garg, Ayush Garg, Ajay Kumar Mahanty and Abhay Agrawal with Hem Securities Ltd., Share India Capital Services Pvt. Ltd. acting as lead manager. Net proceeds will primarily be used towards To meet Working Capital requirements (Rs 110 crore) and Repayment of certain borrowing availed by the Company, in part or full (Rs 90 crore).
On fundamentals, the company is posting revenue growth of 56.3%, a profit margin of 8.7%, return on equity of 17.7% in its most recent reported period. Listed peers in this segment include Powerica Limited (P/E 24.45x) and Cummins India Limited (P/E 64.13x) — useful reference points when evaluating the issue's pricing relative to where the broader sector are trading.
On our data-signal score, the combined signals for this issue currently read strong — the composite picture tilts positive, though not without some caveats. This is a summary of public data, not a recommendation to apply or skip. Past performance does not predict future returns — review the price chart and peer comparison below before trading.
Q-Line Biotech IPO GMP — What It Means
GMP stops mattering once the shares trade — it only ever estimated the listing price. The summary at the top of this page compares the last pre-listing GMP with how the shares actually listed.
See the full Q-Line Biotech GMP history and trend, or learn how grey market premium works and how reliable it is.
Related IPO
No comments yet. Be the first to share your opinion!